This Nature feature explores the growing momentum behind genomic newborn screening, highlighting early evidence that sequencing can identify serious, treatable conditions that traditional newborn screening may miss. It examines major initiatives around the world—including BabySeq, GUARDIAN, BabyScreen+, the UK Generation Study, and BRIDGES-NBS—while considering key questions around scalability, cost, gene selection, interpretation, and the responsible return of results.
